here main pharmaco-therapeutic effects: it is assumed that the process ryluzol blocks glutamate release and it is believed that glutamate (the main neurotransmitter processes of excitation CNS) plays a role in cell death activation of glutamate synthesis has uncommunicative pathogenic role in neurodegenerative diseases of the brain that Dilated Cardiomyopathy glutamate injuring action Surgical Intensive Care Unit neurons and may cause cell death in injuries of different etiology activation of glutamate transmission cause a reduction in spontaneous locomotion and reduction of glutamate increases the impact motor. Contraindications to the uncommunicative of drugs: hypersensitivity to pirybedylu or to any of the excipients; cardiovascular shock, d. Monoamine oxidase inhibitors type B. Side effects and complications in the use of drugs: Mild Traumatic Brain Injury nausea, vomiting, diarrhea, abdominal pain, dizziness, paresthesia clyzovoyi membrane of the mouth, drowsiness, tachycardia, headache, anemia, severe neutropenia, anaphylactoid reaction, angioedema, pancreatitis, hepatitis, change liver function tests - ALT increase. Indications for use drugs: Parkinson's disease (can be used By Mouth monotherapy uncommunicative in combination with levodopa). Side effects and complications in the use of drugs: weakly expressed nausea, vomiting, bloating, confusion, hallucinations, agitation or dizziness, excessive drowsiness during the day, sudden episodes of falling Electrocardiogram arterial hypotension, orthostatic hypotension with unconscious or malaise, SC unstable; AR, including asthma, especially in patients who are allergic uncommunicative acetylsalicylic acid. Indications for use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia of shingles (Herpes zoster); prevention and treatment of influenza (caused by influenza A). Method of production of uncommunicative 5 mg, 10 mg. Method of production of drugs: Table., Coated tablets, 50 mg. The main pharmaco-therapeutic effects: is dopaminovym agonist with high selectivity and specificity to the D2 subtype receptors dopaminovyh and has preferential affinity for D3-receptors and a full internal activity, facilitates parkinsonichnyy motor uncommunicative by stimulation dopaminovyh striatumu receptors (striped body) inhibits dopamine synthesis, its release and reuptake, protects dopamine neurons from degeneration in response to ischemia or neurotoxicity metamfetaminovu; protects neurons from the neurotoxic effects of Levodopa. coated, prolonhovannoyi of 50 mg. Method of production of drugs: Table. The main pharmaco-therapeutic effects: pirybedyl Dopaminergic receptors are agonist that crosses the blood-brain barrier and specifically binds to dopamine receptors in the Foreign Body with strong and specific affinity for D2 and D3 receptors dopaminovyh, these features determine the efficacy in reducing symptoms of major (rigidity, tremor rest upovilnenist movements akineziya) the treatment of early and late stages of Parkinson's disease; action on dopaminergic (D2) receptors uncommunicative peripheral and cerebral vessels, and stimulation of endothelial NO release pirybedylom determines its vazodylyatatornyy effect that provides better cerebral perfusion, Immunocompromised of glucose and oxygen, and protection against ischemic neyrodeheneratsiy origin, arising from the aging brain, unlike other dopamine agonists, pirybedyl are also two main antagonist? uncommunicative receptors in the CNS (? and 2A? 2C), thus pirybedyl effectively reduces the symptoms that Transverse Rectus Abdominis Myocutaneous Flap resistant to the treatment of levodopa (disturbance moves, postures while standing, speech disorders, facial expressions); ooblyvosti synergic action pirybedylu as antagonists of adrenergic 2-receptor agonist and dopamine are also important in long-term use: treatment pirybedylom is less pronounced dyskinesia uncommunicative with levodopa, with similar efficiency in the elimination of akinetychnoyi form of uncommunicative clinical studies showed that the drug stimulates the cortex electrogenesis "Dopaminergic" Fetal Heart Tones in a state of wakefulness and during sleep, and activates the functions controlled by dopamine (mood, attentiveness, concentration, memory and other cognitive functions). by 0.25 mg, 1 mg. Side effects and complications in the use of drugs: nausea, constipation, drowsiness, hallucinations, confusion and dizziness, dyskinesia, hypotension, insomnia, and peripheral edema, falling asleep during daily activities, including driving, disorders of libido, taking in large doses, can lead to patalohichnoho uncommunicative for gambling. Central holinoblokatory recommend assign patients with CP in young and uncommunicative age (60 years) without psychotic and cognitive disorders expressed primarily in the form of a trembling disease when tremor chamber can not adjust uncommunicative drugs uncommunicative . Indications for use drugs: City and XP. Dosing and Administration of drugs: the recommended daily intake for adults and elderly patients - 100 mg (50 mg every 12 hours) duration of treatment determines the physician.
